Background: Acute lymphoblastic leukemia (ALL) accounts for almost one quarter of pediatric cancer in the United States. Despite cooperative group therapeutic trials, there remains a paucity of large cohort data on which to conduct epidemiology and comparative effectiveness research studies.
A cute lymphoblastic leukemia (ALL) is the most common malignancy in children, accounting for almost one quarter of pediatric cancer cases and 77% of pediatric leukemia cases in the United States. 1 Cooperative group trials have led to current therapies with event free survival approaching 85%. 2 Depending on the trial, 1%-2% of ALL patients die during their induction chemotherapy, which represents approximately one tenth of all ALL-associated deaths. [3] [4] [5] Although case fatality rates have improved over time, chemotherapy treatment advances are still needed to reduce treatment-related morbidity.
To date, studies in pediatric ALL have been performed using either single institution trials or cooperative group therapeutic protocols. Although these study populations have effectively tested chemotherapy efficacy hypotheses, they are not well suited to clinical epidemiology and comparative effectiveness research questions. In addition, cooperative group studies are limited strictly to patients participating in a trial. Clinical epidemiology and comparative effectiveness research studies require large sample sizes that include both on and off-protocol therapy patients, as well as daily medication and medical procedure utilization data. To our knowledge, such datasets have not been established either in the United States or European countries for the analysis of pediatric oncology clinical epidemiology questions.
To address this research gap, we sought to assemble and validate a large cohort of patients with newly diagnosed pediatric ALL receiving treatment at 1 of 43 free-standing pediatric institution throughout the United States that contribute to the Pediatric Health Information Systems (PHIS) administrative database. Although PHIS data do not include outpatient data, the initial diagnosis and treatment of pediatric ALL is almost always performed in the inpatient setting. Therefore, the PHIS dataset represents a unique opportunity to identify a cohort of children with this malignancy.
PHIS currently captures approximately 85% of the free-standing pediatric hospitals registered with the National Association of Children's Hospitals and Related Institutions. The hospitals that contribute data to this database serve a diverse population with most of the metropolitan areas in the United States represented. PHIS data include International Classification of Diseases-9 Clinical Modification (ICD-9) discharge diagnoses and procedure codes, as well as day-byday pharmacy billing data. Investigators have used PHIS data to study a wide range of important clinical epidemiology questions, such as the use of steroids in the treatment of meningitis and Henoch-Schonlein purpura, and medical therapy of appendicitis. [6] [7] [8] Recent literature has highlighted the importance of validating the mechanism in which patient cohorts representing a specific disease are assembled from health administrative data. 9 To our knowledge, no investigators have assembled and validated a cohort of patients with de novo ALL from PHIS. We hypothesized that such a cohort could be established within PHIS by utilizing a multistep process that used a combination of ICD-9 discharge diagnosis and procedure codes as well as billing data for various chemotherapy agents typically used in induction therapy for ALL. We hypothesized that this multistep process would result in a higher positive predictive value than, and comparable sensitivity to, using ALL ICD-9 discharge diagnosis codes alone to determine subjects eligible for inclusion into the final cohort. As a measure of external validity, we compared select demographic characteristics of our final cohort to those reported by the Surveillance Epidemiology and End Results (SEER) Program.
MATERIALS AND METHODS

Data Source
PHIS is a comparative pediatric administrative database including inpatient data from 43 not-for-profit, tertiary children's hospitals affiliated with the Child Health Corporation of America (Overland Park, KS). PHIS data are derived from 2 primary data sources within the participating hospitals. The hospital's medical record system provides patient identification, demographics, dates of service, discharge disposition, and up to 40 ICD-9 discharge diagnosis and procedure codes. As PHIS member hospitals do not yet contribute ICD-10 codes, only ICD-9 codes were used when applicable. In addition, the hospital's billing system provides billed resource utilization data for each patient for every hospital day of service. This resource utilization data include all billed pharmaceuticals, laboratory tests (without results), imaging procedures (without results), and supplies. Each patient's vital status at the time of the hospital discharge is also recorded. Patients are assigned a unique identifier in the PHIS database that is preserved for all admissions. Therefore, patients can be followed from 1 inpatient admission to the next.
Oversight of the methods to maintain PHIS data quality is a joint effort between Child Health Corporation of America, Thomson Reuters Healthcare (data processing partner), and participating hospitals. Each hospital uses a uniform file layout created specifically for PHIS with each data element having a detailed definition. After file submission to Thomson Reuters, data quality audits are performed. These audits primarily check for valid entries (eg, valid ICD-9 diagnosis codes) and reasonable patient information (eg, birth weight). Reports are generated that identify errors needing correction. Error rates above predefined threshold values require hospitals to perform a data review and resubmission until error rates fall below the threshold values. Known data quality issues are transparently communicated to all PHIS data users. These data quality reports allow the data users to exclude data for data quality reasons.
Study Cohort Assembly
The source population for this cohort was patients aged 0-21 years admitted to a PHIS-contributing hospital between the dates of January 1, 1999 and December 31, 2009. A 3-step process was performed to assemble a cohort of patients with presumed de novo ALL.
Step 1 included screening the PHIS database to identify a patient's first-hospital admission during which an ICD-9 discharge diagnosis code within the 204.xx subset was assigned. The 204.xx code is not exclusive to patients with newly diagnosed ALL and can refer to patients with de novo, relapsed, or secondary ALL. Patients were excluded if the PHIS data for the hospitalization containing the 204.xx ICD-9 discharge diagnosis code was not complete, for instance if the child was admitted to a PHIS-contributing hospital during periods where that hospital's data were not complete or the patient-specific hospital data were missing (ie, unavailable pharmaceutical billing data). In step 2, patients were excluded if data suggested the presence of an alternative malignancy or receipt of a bone marrow transplant during the index hospital admission. The presence of the former was based on the assignment of an ICD-9 discharge diagnosis code consistent with an additional or alternative malignancy diagnosis (140.xx-239.xx, excluding 204.xx). The latter was based on the presence of an ICD-9 discharge diagnosis (v42.81, v42.82, 279.50, or 996.85) or procedure code (41.0x) consistent with a bone marrow transplant or the billing for a medication (eg, busulfan, melphalan, and thiotepa) consistent with the same. Patients with evidence of hematopoietic stem cell transplantation in their index admission were excluded because this intervention is nearly exclusively used for therapy of relapsed or secondary ALL. In the rare case of a child with primary refractory or very highrisk disease who would require an early transplant for ALL, it is extremely unlikely for the child to receive the transplant in the first admission. Patients who received a stem cell transplant in a subsequent hospital admission were not excluded from the final cohort, as it is plausible that they had de novo ALL during their index hospitalization but had a subsequent medical need for transplantation. Step 3 involved a comprehensive review of the chemotherapy agents billed for during each patient's first identified ALL admission to determine whether such chemotherapy was consistent with induction therapy for de novo ALL.
Before reviewing the PHIS chemotherapy billing data, guidelines were established to guide the execution of step 3. These guidelines included 14 distinct chemotherapy regimens frequently used for induction ALL chemotherapy (available from R.A.). Recognizing that some patients may not receive one of these specific regimens, we also considered 2 additional de novo ALL chemotherapy patterns. Patients who were billed for at least 3 of 4 standard ALL induction chemotherapy agents [vincristine, asparaginase, an anthracycline (daunorubicin or doxorubicin) and a steroid (prednisone, methylprednisone, or dexamethasone)] within a 14-day window during their first ALL admission were identified. Patients started on a regimen consistent with ALL induction therapy but discharged before completion of induction therapy, presumably to complete the regimen in the outpatient setting, were also identified.
Once these a priori chemotherapy guidelines were established, each patient's hospital chemotherapy billing data for up to 60 inpatient days were manually reviewed by study personnel to determine if the patient met criteria for de novo ALL induction therapy. If a patient was billed for chemotherapy consistent with 1 of the 14 defined regimens then they were considered to have received this regimen. Those patients not receiving 1 of the 14 regimens but still meeting criteria for receipt of ALL induction chemotherapy were classified as "ALL Chemotherapy Not Otherwise Specified (NOS)." Patients not satisfying any of these chemotherapy regimen criteria were classified as not having de novo ALL and thus were not included in the final cohort. Finally, the first review of a minority of patients resulted in the designation of an "uncertain" regimen. These "uncertain" regimens were subsequently reviewed by a study committee comprised of 4 study authors (B.T.F., A.E.S., S.R.R., and R.A.). If an "uncertain" regimen was deemed to be consistent with induction chemotherapy by this committee then the patient was included in the cohort as "ALL Chemotherapy Not Otherwise Specified (NOS)," otherwise they were excluded from the final cohort.
The primary chemotherapy review was performed equally by 2 study authors (T.H. and K.T.). To assess the interrater reliability of the 2 reviewers, a 15% sample of the cohort was reviewed by both. The correlation of the 2 reviews for this 15% sample was assessed using the prevalence-adjusted bias-adjusted k-statistic to measure the level of consistency. 10 
Study Cohort Validation
Both the positive predictive value and the sensitivity of the cohort assembly at each of the 3 steps above were determined through hospital chart review for all patients admitted to the Children's Hospital of Philadelphia (CHOP) from 2004 to 2009 (CHOP began PHIS data contribution in 2004). A systematic chart review was performed for each patient in PHIS that was admitted to CHOP to establish whether the patient was truly a de novo ALL case. Members of the study team (B.T.F. and A.S.) reviewed the bone marrow aspirate/biopsy pathology results and the attending oncology clinician's progress notes to determine the actual malignancy diagnosis. In addition, the medical history was reviewed from the admission history and physical to identify any prior malignancies. The chart abstractionists were blinded to the PHIS data at the time of chart review. An internal CHOP ALL registry, which catalogues all new ALL diagnoses at CHOP, was used as the gold standard for patients with de novo ALL at CHOP. The patients from this registry were compared with those patients identified in PHIS and validated by chart review as having de novo ALL to calculate the sensitivity of our cohort assembly mechanism.
The negative predictive value was not calculated as the PHIS database contains millions of non-ALL admissions, which would translate into numerous true-negative patients, and therefore the negative predictive value would be predictably high. Likewise, the number of patients admitted to CHOP without ALL during the period of interest would be numerous enough that the specificity would also be predictably high.
Demographic characteristics (age, race, sex, and ethnicity) were compared with those reported by the National Cancer Institutes' SEER Program from 1992 to 2004 using Pearson's w 2 test. The SEER Program maintains the preeminent national, population-based cancer registry available in the United States. It compiles demographic data on various malignancies and thus is the best available standard for evaluating the demographic characteristics of the PHISbased cohort.
All Cause Mortality
All cause inpatient case fatality rates within 30 days from the admission date of each patient's first hospitalization were calculated at each step of the cohort assembly process. The case fatality rates for those patients included at each step were compared with the case fatality rates for patients excluded at the same step using Pearson's w 2 test.
The above described data compilation, management, and analyses were performed using Microsoft Excel, SAS version 9.2 (Cary, NC) and STATA statistical software version 10.0 (College Station, TX).
RESULTS
The initial query of the PHIS database from January 1999 to December 2009 identified 15,970 unique patient hospital admissions containing the ICD-9 code of 204.xx. The 3-step process narrowed this cohort to 8733 patients with presumed de novo ALL from 39 different free-standing pediatric institutions across the United States (Fig. 1) . Characteristics of the cohort are shown in Table 1 and are compared with those reported from the National Institute of Cancer's SEER Program for 1992-2004. 1 The PHIS and SEER cohorts shared similar sex distribution. Comparison of age and race composition also seemed to be similar, although formal statistical comparison of the 2 patient populations did reveal statistically significant differences.
The sensitivity and positive predictive value for each of the 3 steps of the cohort assembly process are shown in Table 2 . The sensitivity of the ICD-9 discharge diagnosis code for ALL alone was quite high, but the positive predictive value was only 69%. By excluding patients with evidence of another malignancy or receipt of a bone marrow transplant during the first hospitalization and then subsequently using the manual chemotherapy review, the positive predictive value was optimized to 93%. Despite the addition of these more stringent inclusion and exclusion criteria there was only a modest loss of sensitivity to 88%. Table 3 displays the 30-day inpatient mortality rate calculated at each of the 3 steps of the cohort assembly. By including all patients with an ICD-9 code of 204.xx the case fatality rate within 30 days of hospital admission was 1.4% (95% CI, 1.23%-1.60%). After excluding patients with evidence of an alternative malignancy or receipt of a bone marrow transplant during the first identified hospitalization and excluding patients that did not receive an induction chemotherapy regimen during that same first hospitalization, the inpatient case fatality rate within 30 days of hospitalization was recalculated as 0.8% (95% CI, 0.63%-1.01%). The case fatality rates for those patients excluded at each step were significantly higher than the case fatality rates for patients included at the same step (P < 0.0001).
The comparison of the chemotherapy regimen assignments between the 2 reviewers for the 15% sample resulted in a proportion of agreement of 0.98 and a prevalence-adjusted bias-adjusted k-statistic of 0.97.
DISCUSSION
To the best of our knowledge, this is not only the first report of successful assembly and validation of a cohort of pediatric de novo ALL patients from a large health care administrative database but also the first cohort of pediatric or adult hematologic malignancy patients defined with a combined ICD-9 diagnosis code/induction chemotherapy definition. This approach established a cohort that is demographically consistent with the SEER data from 1992 to 2004. Specifically, the cohort characteristics from our dataset appear very similar to the SEER data relative to age, sex, and race. Although formal statistical comparisons demonstrated statistically significant differences for age and race, the actual proportions were very similar, and the statistically significant differences were due to the large sample sizes, rather than clinically meaningful differences. The data element representing ethnicity in the PHIS database is not reliable as it is often coded as missing and thus a comparison of ethnicity rates between the 2 data sources was not possible.
Our data demonstrate that the use of ICD-9 codes alone do not accurately identify pediatric patients with de novo ALL. The commonly used 204.xx series of codes does not differentiate in any way between newly diagnosed, relapsed, and secondary ALL. Therefore, the use of ICD-9 code-based cohort establishment method will lead to substantial patient misclassification (ie, inclusion of patients without de novo ALL) and thus result in biased outcome estimates. To assess the impact of patient misclassification, we calculated the 30day all-cause inpatient case fatality rate at each of the 3 steps of our cohort assembly. Although 30-day all-cause case fatality rates may underestimate induction case fatality rates (as the induction period for some patients may extend beyond 30 days from admission, and a small percentage of patients die before receiving any chemotherapy) they serve as a reasonable approximation. As noted in our results, the Step 1: 237 patients excluded because relevant PHIS data were not complete
Step 2: 2,091 patients excluded due to bone marrow transplant or alternative malignancy
Step 3: 4,909 patients excluded due to the lack of a chemotherapy regimen consistent with de novo ALL inpatient case fatality rate changed significantly from the first to third steps.
A primary reason for this decrease in death was the exclusion of patients with evidence of an alternative malignancy or receipt of a bone marrow transplant often used for therapy of relapsed and secondary ALL. This variation in mortality rates highlights the importance of performing the additional, time-intensive steps to establish a cohort of patients that is more representative of the intended population. After an index admission, a patient could have been readmitted to a non-PHIS institution, and thus it is possible that our data would not capture a mortal outcome at that institution. However, we would anticipate that most non-PHIS centers would immediately transfer a sick pediatric oncology patient to the institution at which the patient's ALL treatment was initiated and thus the likelihood of missing an inpatient death at a non-PHIS center is assumed to be minimal.
The relatively poor performance of ICD-9 codes alone to define a cohort of patients with de novo ALL is not surprising, given the well-described limitations of ICD-9 codes. The inclusion of manual induction chemotherapy review significantly improved the validity of the study cohort. The manual review of chemotherapy was labor intensive, as the reviewer training, data evaluation, and validation required approximately 450 hours of reviewer time. The high reviewer correlation coefficient provides strong evidence that the review process was systematic and accurate. Our data argue that future pediatric or adult research using administrative datasets, such PHIS, Medicare, or Medicaid, will need to perform a similar process to ensure the establishment of a homogeneous study population. In the future, chemotherapy review efficiency may be improved by using programmable review algorithms. Our group is currently evaluating such algorithms in the ALL dataset.
Benchimol et al, 9 recently proposed a set of criteria to guide researchers performing validation studies involving health administrative data and also to guide the reader in assessing the quality of such work. They emphasize the pitfalls of relying solely on ICD-9 codes to identify patient cohorts with a certain disease from health administrative data. They specifically state: "the dissemination of validation studies is vital to advance the field of research using health administrative data and should therefore be reported in peerreviewed publications." Although we performed our validation before the publication of these guidelines, we are confident that our approach is consistent with the general concepts presented. For instance we provided a complete description of the validation cohort, detailed how the reference standard was applied, provided statistics to assess interrater reliability and reported the diagnostic accuracy with 95% CIs of such statistics as sensitivity and positive predictive value.
The primary limitation to our study is that validation occurred at only 1 of the PHIS-contributing pediatric centers due to the limited resources available for this labor intensive approach to cohort definition. PHIS data completeness may vary by center, and thus a similar validation process at other institutions may result in variation in sensitivity estimates. For example, if a hospital's billing data were not accurate for chemotherapy medications, some patients with de novo ALL may have been eliminated in the chemotherapy review stage (step 3), reducing the overall sensitivity of this approach. In addition, our method would not detect a patient who was critically ill at the time of presentation with de novo ALL and died before receiving chemotherapy. Similarly, these patients would be eliminated in the chemotherapy review stage (step 3) reducing the sensitivity. This latter circumstance is extremely rare (approximately 0.3% of all ALL patients) 11 and thus the impact on overall sensitivity is Step 1: presence of ALL ICD-9 code and complete PHIS data 237 108 17 69% (64%-74%) 93% (90%-96%) Step 2: criteria inclusive of step 1 and lack of an ICD-9 diagnosis or procedure code consistent with an alternative malignancy or bone marrow transplant 230 45 24 84% (79%-88%) 91% (86%-94%)
Step expected to be negligible. This potential reduction in sensitivity, however, does not obviate the need for inclusion of induction treatment data in the establishment of a cohort of de novo ALL patients. The absence of chemotherapy data at certain hospitals would not have altered the positive predictive value of our approach, and thus the patients retained in the final cohort are still likely to have de novo ALL making this a viable cohort for future analysis.
In addition, although it is nationally representative in many respects, this cohort was established from large freestanding children's hospitals in the United States, and any subsequent analyses will only be representative of children treated at such institutions across the country. Finally, ALL is most often diagnosed in the inpatient setting but subsequently managed outpatient. Although this dataset will not allow for the investigations specific to outpatient care, it will still provide valuable insight into the provision of inpatient medical resources and outcomes. Specifically, we predict that we will be able to study significant morbid and mortal events after induction, as these events are most likely to result in or occur during hospitalizations.
In summary, this validated cohort provides a novel opportunity to leverage the PHIS database to efficiently conduct clinical epidemiology and comparative effectiveness studies. Importantly, the size and multicenter nature of the cohort will also allow for the evaluation of practice variation across institutions, the comparison of outcomes for patients treated on or off cooperative group trials, and for the investigation of less common but severe comorbid conditions that were previously limited by single center or smaller cohorts. It is clear that the combination of ICD-9 diagnosis codes with data on induction chemotherapy substantially reduced the risk of misclassification in establishing a cohort of de novo ALL. Such methods should be used when utilizing administrative data to study pediatric and adult hematologic malignancies. In the future, we aim to further validate our approach for other patient cohorts such as children with acute myeloid leukemia and those receiving bone marrow transplants.
